Kirkness Jason P, Madronio Melanie, Stavrinou Rosie, Wheatley John R, Amis Terence C
Ludwig Engel Centre for Respiratory Research, Westmead Hospital and University of Sydney, Sydney, New South Wales, Australia 2145.
J Appl Physiol (1985). 2003 Nov;95(5):1761-6. doi: 10.1152/japplphysiol.00488.2003. Epub 2003 Jul 11.
Lowering surface tension (gamma) of upper airway lining liquid (UAL) reduces upper airway opening (anesthetized humans) and closing (anesthetized rabbits) pressures. We now hypothesize that in sleeping obstructive sleep apnea hypopnea syndrome (OSAHS) patients lowering gamma of UAL will enhance upper airway stability and decrease the severity of sleep-disordered breathing. Nine OSAHS patients [respiratory disturbance index (RDI): 49 +/- 8 (SE) events/h, diagnostic night] participated in a two-part, one-night, polysomnography study. In the first part, upper airway closing pressures (during non-rapid eye movement sleep, Pcrit) were measured and samples of UAL (awake) were obtained before and after 2.5 ml of surfactant (Exosurf, Glaxo Smith Kline) was instilled into the posterior pharynx. The gamma of UAL was determined with the use of the "pull-off" force technique. In the second part, subjects received a second application of 2.5 ml of surfactant and then slept the remainder of the night (205 +/- 30 min). Instillation of surfactant decreased the gamma of UAL from 60.9 +/- 3.1 mN/m (control) to 45.2 +/- 2.5 mN/m (surfactant group) (n = 9, P < 0.001). Pcrit decreased from 1.19 +/- 1.14 cmH2O (control) to -0.56 +/- 1.15 cmH2O (surfactant group) (n = 7, P < 0.02). Compared with the second half of diagnostic night, surfactant decreased RDI from 51 +/- 8 to 35 +/- 8 events/h (n = 9, P < 0.03). The fall in RDI (deltaRDI) correlated with the fall in gamma of UAL (deltagamma) (deltaRDI = 1.8 x deltagamma, r = 0.68, P = 0.04). Hypopneas decreased approximately 50% from 42 +/- 8 to 20 +/- 5 events/h (n = 9, P < 0.03, paired t-test). The gamma of UAL measured the next morning remained low at 49.5 +/- 2.7 mN/m (n = 9, P < 0.001, ANOVA, compared with control). In conclusion, instillation of surfactant reduced the gamma of UAL in OSAHS patients and decreased Pcrit and the occurrence of hypopneas. Therapeutic manipulation of gamma of UAL may be beneficial in reducing the severity of sleep-disordered breathing in OSAHS patients.
降低上气道衬液(UAL)的表面张力(γ)可降低上气道开口压(麻醉状态下的人类)和关闭压(麻醉状态下的兔子)。我们现在推测,在睡眠呼吸暂停低通气综合征(OSAHS)患者中,降低UAL的γ值将增强上气道稳定性,并降低睡眠呼吸紊乱的严重程度。9名OSAHS患者[呼吸紊乱指数(RDI):49±8(标准误)次/小时,诊断夜]参与了一项为期两部分、持续一晚的多导睡眠图研究。在第一部分中,测量上气道关闭压(非快速眼动睡眠期间,Pcrit),并在将2.5毫升表面活性剂(Exosurf,葛兰素史克公司)滴入下咽前后获取(清醒状态下的)UAL样本。使用“拉脱”力技术测定UAL的γ值。在第二部分中,受试者再次接受2.5毫升表面活性剂滴注,然后睡完余下的夜晚(205±30分钟)。滴注表面活性剂使UAL的γ值从60.9±3.1毫牛顿/米(对照组)降至45.2±2.5毫牛顿/米(表面活性剂组)(n = 9,P < 0.001)。Pcrit从1.19±1.14厘米水柱(对照组)降至 -0.56±1.15厘米水柱(表面活性剂组)(n = 7,P < 0.02)。与诊断夜的后半段相比,表面活性剂使RDI从51±8次/小时降至35±8次/小时(n = 9,P < 0.03)。RDI的下降(ΔRDI)与UAL的γ值下降(Δγ)相关(ΔRDI = 1.8×Δγ,r = 0.68,P = 0.04)。呼吸暂停低通气次数从42±8次/小时降至20±5次/小时,减少了约50%(n = 9,P < 0.03,配对t检验)。第二天早上测得的UAL的γ值仍较低,为49.5±2.7毫牛顿/米(n = 9,P < 0.001,方差分析,与对照组相比)。总之,滴注表面活性剂降低了OSAHS患者UAL的γ值,降低了Pcrit以及呼吸暂停低通气的发生率。对UAL的γ值进行治疗性调控可能有助于降低OSAHS患者睡眠呼吸紊乱的严重程度。